Improvement in the 95-95-95 Targets Is Accompanied by a Reduction in Both the Human Immunodeficiency Virus Transmission Rate and Incidence in China,The Journal of Infectious Diseases

当前位置： X-MOL 学术 › J. Infect. Dis. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Improvement in the 95-95-95 Targets Is Accompanied by a Reduction in Both the Human Immunodeficiency Virus Transmission Rate and Incidence in China
The Journal of Infectious Diseases ( IF 5.0 ) Pub Date : 2024-08-26 , DOI: 10.1093/infdis/jiae302
Jingrong Ye ₁ , Yun Lan ₂ , Juan Wang ₁ , Yi Feng ₃ , Yi Lin _{4,

5,

6} , Ying Zhou ₇ , Jinjin Liu ₈ , Dan Yuan ₉ , Xinli Lu ₁₀ , Weigui Guo ₁₁ , Minna Zheng ₁₂ , Xiao Song ₁₃ , Quanhua Zhou ₁₄ , Hong Yang ₁₅ , Chenli Zheng ₁₆ , Qi Guo ₁₇ , Xiaohui Yang ₁₈ , Kai Yang ₁₉ , Lincai Zhang ₂₀ , Zhangwen Ge ₂₁ , Lifeng Liu ₂₂ , Fengting Yu ₂₃ , Yang Han ₂₄ , Huihuang Huang ₂₅ , Mingqiang Hao ₁ , Qiang Chen ₁ , Xuemei Ling ₂ , Yuhua Ruan ₃ , Yuan Dong _{4,

5,

6} , Chang Zhou ₉ , Xuangu Liu ₁₁ , Jianyun Bai ₁₂ , Xue Tong ₁₃ , Ya Gao ₁₅ , Zhengrong Yang ₁₆ , Ao Wang ₁₇ , Wei Wei ₁₈ , Fanghua Mei ₁₉ , Ruijuan Qiao ₂₀ , Xinhua Luo ₂₁ , Xiaojie Huang ₂₂ , Jing Chen ₁ , Fengyu Hu ₂ , Xin Shen _{4,

5,

6} , Wei Tan ₁₆ , Aixia Tu ₂₀ , Xinhui Zhang ₂₆ , Shufang He ₁ , Zhen Ning _{4,

5,

6} , Jixiang Fan ₁₇ , Cong Liu ₁₉ , Conghui Xu ₁ , Xianlong Ren ₁ , Yanming Sun ₁ , Yang Li ₁ , Guowu Liu ₁ , Xiyao Li ₁ , Jie Li ₁ , Junyi Duan ₂₂ , Tao Huang ₂₂ , Shuiqing Liu ₂₇ , Guolong Yu ₂₈ , Donglin Wu ₁₇ , Yiming Shao ₃ , Qichao Pan _{4,

5,

6} , Linglin Zhang ₉ , Bin Su ₂₂ , Jianjun Wu ₂₉ , Tianjun Jiang ₂₅ , Hongxin Zhao ₂₃ , Tong Zhang ₂₂ , Faqing Chen ₂₀ , Kun Cai ₁₉ , Bing Hu ₁₈ , Hui Wang ₁₇ , Jin Zhao ₁₆ , Baicheng Gao ₁₅ , Wei Sun ₁₃ , Tielin Ning ₁₂ , Jianjun Li ₃₀ , Shu Liang ₉ , Yuqi Huo ₈ , Gengfeng Fu ₇ , Xin Chen _{4,

5,

6} , Feng Li ₂ , Hui Xing ₃ , Hongyan Lu ₁

Affiliation

Institute for HIV/AIDS and STD Prevention and Control, Beijing Center for Disease Control and Prevention (CDC), Beijing Academy of Preventive Medicine, Beijing.
Institute of Infectious Diseases, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou.
Division of Virology and Immunology, State Key Laboratory for Infectious Disease Prevention and Control and National Center for AIDS/STD Prevention and Control, China CDC, Beijing.
Division of Tuberculosis and HIV/AIDS Prevention, Shanghai CDC.
Shanghai Institutes of Preventive Medicine.
Shanghai Center for AIDS Research, Shanghai.
Institute of AIDS/STD Control and Prevention, Jiangsu CDC, Nanjing.
Center for Translational Medicine, Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, The Sixth People's Hospital of Zhengzhou), Zhengzhou.
Center for AIDS/STD Control and Prevention, Sichuan CDC, Chengdu.
Department of AIDS Research, Hebei Key Laboratory of Pathogen and Epidemiology of Infectious Disease, Hebei CDC, Shijiazhuang.
Institute of HIV/AIDS Prevention and Control, Beihai CDC, Beihai.
Department of STDs/AIDS Control and Prevention, Tianjin CDC, Tianjin.
Institute for HIV/AIDS and STD Prevention and Control, Heilongjiang CDC, Harbin.
Institute of Microbiology, Chongqing CDC, Chongqing.
STD/AIDS Prevention and Control Institute, Inner Mongolia CDC (Inner Mongolia Academy of Preventive Medicine), Hohhot.
Department of HIV/AIDS Control and Prevention, Shenzhen CDC, Shenzhen.
Virology Laboratory, Jilin CDC, Changchun.
Institute for HIV/AIDS and STD Prevention and Control, Fuyang CDC, Fuyang.
Hubei CDC, Wuhan.
Institute for HIV/AIDS and STD Prevention and Control, Gansu CDC, Lanzhou.
Guizhou Provincial People's Hospital, Affiliated Hospital of Guizhou University, Guiyang.
Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing.
Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing.
Department of Infectious Disease, Peking Union Medical College Hospital, Beijing.
Treatment and Research Center for Infectious Diseases, The Fifth Medical Center of People's Liberation Army General Hospital, Beijing.
Institute for Infectious Disease Prevention and Control, Guizhou CDC, Guiyang.
Department of Infectious Diseases, Guiyang Public Health Clinical Center, Guiyang.
Institute of Pathogenic Microbiology, Guangdong CDC, Guangzhou.
Institute for HIV/AIDS and STD Prevention and Control, Anhui CDC, Hefei.
Institute of HIV/AIDS Prevention and Control, Guangxi CDC, Nanning.

Background In 2016, China has implemented the World Health Organization's “treat all” policy. We aimed to assess the impact of significant improvements in the 95-95-95 targets on population-level human immunodeficiency virus (HIV) transmission dynamics and incidence. Methods We focused on 3 steps of the HIV care continuum: diagnosed, on antiretroviral therapy, and achieving viral suppression. The molecular transmission clusters were inferred using HIV-TRACE. New HIV infections were estimated using the incidence method in the European Centre for Disease Prevention and Control HIV Modelling Tool. Results Between 2004 and 2023, the national HIV epidemiology database recorded 2.99 billion person-times of HIV tests and identified 1 976 878 new diagnoses. We noted a roughly “inverted-V” curve in the clustering frequency, with the peak recorded in 2014 (67.1% [95% confidence interval, 63.7%–70.5%]), concurrent with a significant improvement in the 95-95-95 targets from 10-13-<71 in 2005 to 84-93-97 in 2022. Furthermore, we observed a parabolic curve for a new infection with the vertex occurring in 2010. Conclusions In general, it was suggested that the improvements in the 95-95-95 targets were accompanied by a reduction in both the population-level HIV transmission rate and incidence. Thus, China should allocate more effort to the first “95” target to achieve a balanced 95-95-95 target.

更新日期：2024-08-26

点击分享查看原文

点击收藏

阅读更多本刊新发论文